Current Food and Drug Administration–approved medications in the United States for prevention or treatment of osteoporosis fall into 1 of 2 categories. The first includes antiresorptive drugs, which inhibit bone resorption, with a subsequent reduction in coupled bone formation. These drugs increase bone mineral density (BMD), but this is due largely to refilling of bone remodeling cavities and an increase in mineralization density. There is no evidence that any of these agents lead to deposition of new bone. Antiresorptive drugs include the bisphosphonates (alendronate, risedronate, ibandronate, and zolendronic acid), a selective estrogen receptor modulator (raloxifene), estrogen, calcitonin, and a monoclonal antibody against receptor activator of nuclear factor-κB ligand (denosumab). The second category includes formation-stimulating drugs, of which teriparatide is the only member.1 Teriparatide stimulates new bone formation and thus has the potential to reverse (rather than just prevent) bone loss. However, with the exceptions of generic alendronate and estrogen, all of these therapies, particularly teriparatide, are relatively expensive.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 7
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.